Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 361

1.

Interleukin 17A Participates in Renal Inflammation Associated to Experimental and Human Hypertension.

Orejudo M, Rodrigues-Diez RR, Rodrigues-Diez R, Garcia-Redondo A, Santos-Sánchez L, Rández-Garbayo J, Cannata-Ortiz P, Ramos AM, Ortiz A, Selgas R, Mezzano S, Lavoz C, Ruiz-Ortega M.

Front Pharmacol. 2019 Sep 13;10:1015. doi: 10.3389/fphar.2019.01015. eCollection 2019.

2.

Natural Plants Compounds as Modulators of Epithelial-to-Mesenchymal Transition.

Avila-Carrasco L, Majano P, Sánchez-Toméro JA, Selgas R, López-Cabrera M, Aguilera A, González Mateo G.

Front Pharmacol. 2019 Jul 30;10:715. doi: 10.3389/fphar.2019.00715. eCollection 2019. Review.

3.

The ideal position of the peritoneal dialysis catheter is not always ideal.

Tanasiychuk T, Selgas R, Kushnir D, Abd Elhalim M, Antebi A, Del Peso G, Bajo MA, Frajewicki V.

Int Urol Nephrol. 2019 Oct;51(10):1867-1872. doi: 10.1007/s11255-019-02177-3. Epub 2019 Jul 1.

PMID:
31264086
4.

Abnormalities in Glucose Metabolism, Appetite-Related Peptide Release, and Pro-inflammatory Cytokines Play a Central Role in Appetite Disorders in Peritoneal Dialysis.

Avila-Carrasco L, Pavone MA, González E, Aguilera-Baca Á, Selgas R, Del Peso G, Cigarran S, López-Cabrera M, Aguilera A.

Front Physiol. 2019 May 28;10:630. doi: 10.3389/fphys.2019.00630. eCollection 2019.

5.

Severe congenital nephrogenic diabetes insipidus in a compound heterozygote with a new large deletion of the AQP2 gene. A case report.

Peces R, Mena R, Peces C, Santos-Simarro F, Fernández L, Afonso S, Lapunzina P, Selgas R, Nevado J.

Mol Genet Genomic Med. 2019 Apr;7(4):e00568. doi: 10.1002/mgg3.568. Epub 2019 Feb 19.

6.

Multicenter Validation of the Emotional State Instrument for Dialysis Patients.

Rodríguez-Rey R, García-Llana H, Ruiz-Álvarez MP, Gómez-Gómez A, Del Peso G, Selgas R.

Nurs Res. 2019 Jan/Feb;68(1):39-47. doi: 10.1097/NNR.0000000000000321.

PMID:
30540692
7.

Gremlin Regulates Tubular Epithelial to Mesenchymal Transition via VEGFR2: Potential Role in Renal Fibrosis.

Marquez-Exposito L, Lavoz C, Rodrigues-Diez RR, Rayego-Mateos S, Orejudo M, Cantero-Navarro E, Ortiz A, Egido J, Selgas R, Mezzano S, Ruiz-Ortega M.

Front Pharmacol. 2018 Oct 17;9:1195. doi: 10.3389/fphar.2018.01195. eCollection 2018.

8.

Prominent Levels of the Profibrotic Chemokine CCL18 during Peritonitis: In Vitro Downregulation by Vitamin D Receptor Agonists.

Ossorio M, Martínez V, Bajo MA, Del Peso G, Castro MJ, Romero S, Selgas R, Bellón T.

Biomed Res Int. 2018 Apr 4;2018:6415892. doi: 10.1155/2018/6415892. eCollection 2018.

9.

Paricalcitol and Peritoneal Protein Loss in Peritoneal Dialysis: A Double-Center Study.

Jerónimo T, Malho Guedes A, Del Peso G, Silva AP, Selgas R, Bajo MA, Neves PL.

Blood Purif. 2018;46(2):103-110. doi: 10.1159/000488637. Epub 2018 Apr 19.

PMID:
29672317
10.

Acute renal failure and severe neurotoxicity after unintentional overdose of valacyclovir in a geriatric population: A case report.

Ferreira M, Vega C, Rivas B, Selgas R.

Nefrologia. 2018 May - Jun;38(3):323-325. doi: 10.1016/j.nefro.2017.05.007. Epub 2018 Mar 7. English, Spanish. No abstract available.

11.

Cytomegalovirus infection after kidney transplantation and long-term graft loss.

López-Oliva MO, Flores J, Madero R, Escuin F, Santana MJ, Bellón T, Selgas R, Jiménez C.

Nefrologia. 2017 Sep - Oct;37(5):515-525. doi: 10.1016/j.nefro.2016.11.018. English, Spanish.

12.

Living kidney transplantation between brothers with unrecognized renal amyloidosis as the first manifestation of familial Mediterranean fever: a case report.

Peces R, Afonso S, Peces C, Nevado J, Selgas R.

BMC Med Genet. 2017 Aug 31;18(1):97. doi: 10.1186/s12881-017-0457-9.

13.

Protein-energy wasting syndrome in advanced chronic kidney disease: prevalence and specific clinical characteristics.

Pérez-Torres A, González Garcia ME, San José-Valiente B, Bajo Rubio MA, Celadilla Diez O, López-Sobaler AM, Selgas R.

Nefrologia. 2018 Mar - Apr;38(2):141-151. doi: 10.1016/j.nefro.2017.06.004. Epub 2017 Jul 26. English, Spanish.

14.

Mechanisms Involved in Hypersensitivity Reactions to Polysulfone Hemodialysis Membranes.

Rodríguez-Sanz A, Sánchez-Villanueva R, Domínguez-Ortega J, Fiandor AM, Ruiz MP, Trocoli F, Díaz-Tejeiro R, Cadenillas C, González E, Martínez V, López-Trascasa M, Quirce S, Selgas R, Bellón T.

Artif Organs. 2017 Nov;41(11):E285-E295. doi: 10.1111/aor.12954. Epub 2017 Jul 19.

PMID:
28722144
15.

Short-term efficacy and safety of treatment with febuxostat in kidney transplant recipient. An unicentric observational study.

Ferreira M, Jiménez C, Lopez MO, González E, Santana MJ, Selgas R.

Nefrologia. 2018 May - Jun;38(3):331-332. doi: 10.1016/j.nefro.2017.03.020. Epub 2017 Jun 2. English, Spanish. No abstract available.

16.

Relationship between bioimpedance-determined body composition and peritoneal transport in peritoneal dialysis.

da Costa BM, Del Peso G, Bajo MA, Carreño G, Ferreira M, Ferreira C, Selgas R.

Int J Artif Organs. 2017 May 29;40(5):212-218. doi: 10.5301/ijao.5000584. Epub 2017 May 18.

PMID:
28525669
17.

Improvement in Nutritional Status in Patients With Chronic Kidney Disease-4 by a Nutrition Education Program With No Impact on Renal Function and Determined by Male Sex.

Pérez-Torres A, González Garcia E, Garcia-Llana H, Del Peso G, López-Sobaler AM, Selgas R.

J Ren Nutr. 2017 Sep;27(5):303-310. doi: 10.1053/j.jrn.2017.02.004. Epub 2017 Apr 20.

PMID:
28434761
18.

Correction: Nebivolol, a β1-adrenergic blocker, protects from peritoneal membrane damage induced during peritoneal dialysis.

Liappas G, González-Mateo G, Aguirre AR, Abensur H, Albar-Vizcaino P, Parra EG, Sandoval P, Ramírez LG, Del Peso G, Acedo JM, Bajo MA, Selgas R, Sánchez Tomero JA, López-Cabrera M, Aguilera A.

Oncotarget. 2017 Apr 4;8(14):24045. doi: 10.18632/oncotarget.16782. No abstract available.

19.

Sustained low peritoneal effluent CCL18 levels are associated with preservation of peritoneal membrane function in peritoneal dialysis.

Ossorio M, Bajo MA, Del Peso G, Martínez V, Fernández M, Castro MJ, Rodríguez-Sanz A, Madero R, Bellón T, Selgas R.

PLoS One. 2017 Apr 17;12(4):e0175835. doi: 10.1371/journal.pone.0175835. eCollection 2017.

20.

Genomic reprograming analysis of the Mesothelial to Mesenchymal Transition identifies biomarkers in peritoneal dialysis patients.

Ruiz-Carpio V, Sandoval P, Aguilera A, Albar-Vizcaíno P, Perez-Lozano ML, González-Mateo GT, Acuña-Ruiz A, García-Cantalejo J, Botías P, Bajo MA, Selgas R, Sánchez-Tomero JA, Passlick-Deetjen J, Piecha D, Büchel J, Steppan S, López-Cabrera M.

Sci Rep. 2017 Mar 22;7:44941. doi: 10.1038/srep44941.

21.

Body composition analysis and adipocytokine concentrations in haemodialysis patients: abdominal fat gain as an additional cardiovascular risk factor.

González E, Díez JJ, Pérez Torres A, Bajo MA, Del Peso G, Sánchez-Villanueva R, Grande C, Rodríguez O, Coronado M, Gómez Candela C, Díaz-Almirón M, Iglesias P, Selgas R.

Nefrologia. 2017 Mar - Apr;37(2):138-148. doi: 10.1016/j.nefro.2016.06.007. Epub 2016 Oct 27. English, Spanish.

22.

Corrigendum to "T Helper 17/Regulatory T Cell Balance and Experimental Models of Peritoneal Dialysis-Induced Damage".

Liappas G, Gónzalez-Mateo GT, Majano P, Sánchez-Tomero JA, Ruiz-Ortega M, Rodrigues Díez R, Martín P, Sanchez-Díaz R, Selgas R, López-Cabrera M, Aguilera Peralta A.

Biomed Res Int. 2017;2017:6130208. doi: 10.1155/2017/6130208. Epub 2017 Feb 8.

23.

How a Bottom-Up Multi-Stakeholder Initiative Helped Transform the Renal Replacement Therapy Landscape in Spain.

Selgas R, Rodriguez L, Julian JC, Remon C, Prieto-Velasco M, Perez-Contreras J, Fontan MP; GADDPE.

Appl Health Econ Health Policy. 2017 Dec;15(6):755-762. doi: 10.1007/s40258-017-0315-0.

24.

Switch to belatacept in kidney graft recipients.

López-Oliva MO, Álvarez L, Testillano ML, Pérez T, Nieto MF, Santana MJ, González E, Herrero A, Selgas R, Jiménez C.

Nefrologia. 2017 Sep - Oct;37(5):550-552. doi: 10.1016/j.nefro.2016.11.001. Epub 2017 Feb 21. English, Spanish. No abstract available.

25.

Thyroid dysfunction and kidney disease: An update.

Iglesias P, Bajo MA, Selgas R, Díez JJ.

Rev Endocr Metab Disord. 2017 Mar;18(1):131-144. doi: 10.1007/s11154-016-9395-7. Review.

PMID:
27864708
26.

The Communication and Bioethical Training (CoBiT) Program for assisting dialysis decision-making in Spanish ACKD units.

García-Llana H, Bajo MA, Barbero J, Selgas R, Del Peso G.

Psychol Health Med. 2017 Apr;22(4):474-482. doi: 10.1080/13548506.2016.1199888. Epub 2016 Jun 23.

PMID:
27335100
27.

Preventing peritoneal membrane fibrosis in peritoneal dialysis patients.

Zhou Q, Bajo MA, Del Peso G, Yu X, Selgas R.

Kidney Int. 2016 Sep;90(3):515-24. doi: 10.1016/j.kint.2016.03.040. Epub 2016 Jun 7. Review.

PMID:
27282936
28.

Immune-Regulatory Molecule CD69 Controls Peritoneal Fibrosis.

Liappas G, González-Mateo GT, Sánchez-Díaz R, Lazcano JJ, Lasarte S, Matesanz-Marín A, Zur R, Ferrantelli E, Ramírez LG, Aguilera A, Fernández-Ruiz E, Beelen RH, Selgas R, Sánchez-Madrid F, Martín P, López-Cabrera M.

J Am Soc Nephrol. 2016 Dec;27(12):3561-3576. Epub 2016 May 5.

29.

Nebivolol, a β1-adrenergic blocker, protects from peritoneal membrane damage induced during peritoneal dialysis.

Liappas G, González-Mateo G, Aguirre AR, Abensur H, Albar-Vizcaino P, Parra EG, Sandoval P, Ramírez LG, Del Peso G, Acedo JM, Bajo MA, Selgas R, Sánchez Tomero JA, López-Cabrera M, Aguilera A.

Oncotarget. 2016 May 24;7(21):30133-46. doi: 10.18632/oncotarget.8780. Erratum in: Oncotarget. 2017 Apr 4;8(14 ):24045.

30.

Fibroblast Growth Factor 21 (FGF-21) in Peritoneal Dialysis Patients: Natural History and Metabolic Implications.

González E, Díez JJ, Bajo MA, del Peso G, Grande C, Rodríguez O, Díaz-Almirón M, Iglesias P, Selgas R.

PLoS One. 2016 Mar 17;11(3):e0151698. doi: 10.1371/journal.pone.0151698. eCollection 2016.

31.

The Natural History of Kidney Graft Cortical Microcirculation Determined by Real-Time Contrast-Enhanced Sonography (RT-CES).

Jiménez C, López MO, Ros A, Aguilar A, Menendez D, Rivas B, Santana MJ, Vaca MA, Escuin F, Madero R, Selgas R.

PLoS One. 2016 Mar 7;11(3):e0150384. doi: 10.1371/journal.pone.0150384. eCollection 2016.

32.

Rapamycin Protects from Type-I Peritoneal Membrane Failure Inhibiting the Angiogenesis, Lymphangiogenesis, and Endo-MT.

González-Mateo GT, Aguirre AR, Loureiro J, Abensur H, Sandoval P, Sánchez-Tomero JA, del Peso G, Jiménez-Heffernan JA, Ruiz-Carpio V, Selgas R, López-Cabrera M, Aguilera A, Liappas G.

Biomed Res Int. 2015;2015:989560. doi: 10.1155/2015/989560. Epub 2015 Nov 25.

33.

An Increase of Plasma Advanced Oxidation Protein Products Levels Is Associated with Cardiovascular Risk in Incident Peritoneal Dialysis Patients: A Pilot Study.

Gonzalez E, Bajo MA, Carrero JJ, Lindholm B, Grande C, Sánchez-Villanueva R, Del Peso G, Díaz-Almirón M, Iglesias P, Díez JJ, Selgas R.

Oxid Med Cell Longev. 2015;2015:219569. doi: 10.1155/2015/219569. Epub 2015 Oct 25.

34.

Biocompatible Dialysis Solutions Preserve Peritoneal Mesothelial Cell and Vessel Wall Integrity. A Case-Control Study on Human Biopsies.

del Peso G, Jiménez-Heffernan JA, Selgas R, Remón C, Ossorio M, Fernández-Perpén A, Sánchez-Tomero JA, Cirugeda A, de Sousa E, Sandoval P, Díaz R, López-Cabrera M, Bajo MA.

Perit Dial Int. 2016 Mar-Apr;36(2):129-34. doi: 10.3747/pdi.2014.00038. Epub 2015 Oct 16.

35.

TGF-Beta Blockade Increases Renal Inflammation Caused by the C-Terminal Module of the CCN2.

Rodrigues-Díez R, Rayego-Mateos S, Orejudo M, Aroeira LS, Selgas R, Ortiz A, Egido J, Ruiz-Ortega M.

Mediators Inflamm. 2015;2015:506041. doi: 10.1155/2015/506041. Epub 2015 May 5.

36.

T Helper 17/Regulatory T Cell Balance and Experimental Models of Peritoneal Dialysis-Induced Damage.

Liappas G, Gónzalez-Mateo GT, Majano P, Sánchez-Tomero JA, Ruiz-Ortega M, Rodrigues Díez R, Martín P, Sanchez-Díaz R, Selgas R, López-Cabrera M, Aguilera Peralta A.

Biomed Res Int. 2015;2015:416480. doi: 10.1155/2015/416480. Epub 2015 May 3. Review. Erratum in: Biomed Res Int. 2017;2017:6130208.

37.

Biocompatibility reduces inflammation-induced apoptosis in mesothelial cells exposed to peritoneal dialysis fluid.

Santamaría B, Ucero AC, Benito-Martin A, Vicent MJ, Orzáez M, Celdrán A, Selgas R, Ruíz-Ortega M, Ortiz A.

Blood Purif. 2015;39(1-3):200-9.

PMID:
25765663
38.

Albumin-induced apoptosis of tubular cells is modulated by BASP1.

Sanchez-Niño MD, Fernandez-Fernandez B, Perez-Gomez MV, Poveda J, Sanz AB, Cannata-Ortiz P, Ruiz-Ortega M, Egido J, Selgas R, Ortiz A.

Cell Death Dis. 2015 Feb 12;6:e1644. doi: 10.1038/cddis.2015.1.

39.

Synthesis and biological evaluation of pyridazino[1',6':1,2]pyrido[3,4-b]indolinium and pyridazino[1,6-a]benzimidazolium salts as anti-inflammatory agents.

Rodríguez-Sanz A, Sánchez-Alonso P, Bellón T, Alajarín R, Martínez-Cabeza V, Selgas R, Vaquero JJ, Álvarez-Builla J.

Eur J Med Chem. 2015 Mar 26;93:83-92. doi: 10.1016/j.ejmech.2015.01.060. Epub 2015 Jan 31.

PMID:
25659754
40.

Peritoneal Dialysis Can Be an Option for Dominant Polycystic Kidney Disease: an Observational Study.

Janeiro D, Portolés J, Tato AM, López-Sánchez P, Del Peso G, Rivera M, Castellano I, Fernández-Reyes MJ, Pérez-Gómez V, Ortega M, Martínez-Miguel P, Felipe C, Caparrós G, Ortiz A, Selgas R; Grupo Centro de Diálisis Peritoneal (GCDP).

Perit Dial Int. 2015 Sep-Oct;35(5):530-6. doi: 10.3747/pdi.2014.00029. Epub 2014 Oct 7.

41.

Peritoneal resting with heparinized lavage reverses peritoneal type I membrane failure. A comparative study of the resting effects on normal membranes.

De Sousa E, Del Peso G, Alvarez L, Ros S, Mateus A, Aguilar A, Selgas R, Bajo MA.

Perit Dial Int. 2014 Nov-Dec;34(7):698-705. doi: 10.3747/pdi.2013.00286. Epub 2014 Oct 7.

42.

Paricalcitol reduces peritoneal fibrosis in mice through the activation of regulatory T cells and reduction in IL-17 production.

González-Mateo GT, Fernández-Míllara V, Bellón T, Liappas G, Ruiz-Ortega M, López-Cabrera M, Selgas R, Aroeira LS.

PLoS One. 2014 Oct 3;9(10):e108477. doi: 10.1371/journal.pone.0108477. eCollection 2014.

43.

The role of depression, anxiety, stress and adherence to treatment in dialysis patients’ health-related quality of life: a systematic review of the literature.

García-Llana H, Remor E, Del Peso G, Selgas R.

Nefrologia. 2014;34(5):637-57. doi: 10.3265/Nefrologia.pre2014.Jun.11959. Review. English, Spanish.

44.

Mitochondria-targeted therapies for acute kidney injury.

Tábara LC, Poveda J, Martin-Cleary C, Selgas R, Ortiz A, Sanchez-Niño MD.

Expert Rev Mol Med. 2014 Aug 8;16:e13. doi: 10.1017/erm.2014.14. Review. Erratum in: Expert Rev Mol Med. 2014;16:e14.

PMID:
25104110
45.

Hypersensitivity reactions to synthetic haemodialysis membranes.

Sánchez-Villanueva RJ, González E, Quirce S, Díaz R, Alvarez L, Menéndez D, Rodríguez-Gayo L, Bajo MA, Selgas R.

Nefrologia. 2014;34(4):520-5. doi: 10.3265/Nefrologia.pre2014.May.12552. English, Spanish.

46.

Pseudopheochromocytoma as a cause of resistant and paroxysmal hypertension successfully treated by percutaneous renal denervation.

Costero O, Sánchez-Recalde A, Moreno R, Moreno I, Selgas R, López-Sendón JL.

Rev Esp Cardiol (Engl Ed). 2013 Mar;66(3):227-9. doi: 10.1016/j.rec.2012.07.018. Epub 2012 Nov 10. No abstract available.

PMID:
24775462
47.

High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies.

Castillo I, Martinez-Ara J, Olea T, Bartolomé J, Madero R, Hernández E, Bernis C, Aguilar A, Quiroga JA, Carreño V, Selgas R.

Kidney Int. 2014 Sep;86(3):619-24. doi: 10.1038/ki.2014.68. Epub 2014 Mar 19.

48.

TWEAK promotes peritoneal inflammation.

Sanz AB, Aroeira LS, Bellon T, del Peso G, Jimenez-Heffernan J, Santamaria B, Sanchez-Niño MD, Blanco-Colio LM, Lopez-Cabrera M, Ruiz-Ortega M, Egido J, Selgas R, Ortiz A.

PLoS One. 2014 Mar 5;9(3):e90399. doi: 10.1371/journal.pone.0090399. eCollection 2014.

49.

Can EPS development be avoided with early interventions? The potential role of tamoxifen--a single-center study.

De Sousa-Amorim E, Del Peso G, Bajo MA, Alvarez L, Ossorio M, Gil F, Bellon T, Selgas R.

Perit Dial Int. 2014 Sep-Oct;34(6):582-93. doi: 10.3747/pdi.2012.00286. Epub 2014 Mar 1.

50.

IL-17A is a novel player in dialysis-induced peritoneal damage.

Rodrigues-Díez R, Aroeira LS, Orejudo M, Bajo MA, Heffernan JJ, Rodrigues-Díez RR, Rayego-Mateos S, Ortiz A, Gonzalez-Mateo G, López-Cabrera M, Selgas R, Egido J, Ruiz-Ortega M.

Kidney Int. 2014 Aug;86(2):303-15. doi: 10.1038/ki.2014.33. Epub 2014 Feb 19.

Supplemental Content

Loading ...
Support Center